Short-term growth hormone administration at the time of opportunistic infections in HIV-positive patients.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

Wasting in HIV disease is often episodic, coinciding with bouts of acute opportunistic infection.

Who Took Part

PubMed indexes the participants as adults, men only.

Principal assessments were protein metabolism (measured by 13C-leucine infusion), body composition (measured by DEXA) and safety.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

A placebo (an inactive look-alike) gave the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group a baseline to be compared against.

What Was Measured

The subject headings attached to it are AIDS-Related Opportunistic Infections, Body Composition, Growth Hormone, HIV Wasting Syndrome, Hand Strength, Human Growth Hormone and Proteins.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 1999 (AIDS (London, England)), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.